Technical Service Need help? Our team of experienced experts is here for you with full support.
AKA-238
Revumenib
Cat. No.
AKA-238
CAS No.
2169919-21-3
MF
C32H47FN6O4S
MW
630.8
Revumenib is a potent, specific Menin-MLL inhibitor.
Advanced Equipments & Extensive Production Expertise
Commercial Manufacturing
Stable Quality
Customization Supporting
Technical Service 
86-28-85159085 
info@aktin.com Technical Data
Description
Documents
Storage and Shipping
References
Product Name
Revumenib
CAS No.
2169919-21-3
MF
C32H47FN6O4S
MW
630.8
Specification
98.0%–102.0% on anhydrous basis
Research Area
Cytochrome P450 CYP3A4 inhibitor
Disclaimer
This product is intended solely for scientific research or regulatory filing purposes. We do not provide products or services to individuals, please strictly comply with all applicable laws, regulations, and the committed use. Use for any other purpose is strictly prohibited.
Description
Revumenib is a potent, specific Menin-MLL inhibitor. Packing: 10mg, 20mg, 50mg, 100mg, 500mg, 1g, 5g, 10g, 1kg Availability: In stock
Documents
Can't find the right version? Our team of experienced experts is here for you with full support.Contact Us
Storage and Shipping
Store in a cool & dry place, keep away from strong light and heat.
References
[1]. Klossowski S, et al. Menin inhibitor MI-3454 induces remission in MLL1-rearranged and NPM1-mutated models of leukemia. The Journal of Clinical Investigation. 2020;130(2):981-997.
[2]. Issa GC, et al. The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia. Nature. 2023;615(7954):920-924.
[3]. Perner F, et al. MEN1 mutations mediate clinical resistance to menin inhibition. Nature. 2023;615(7954):913-919.
Related Products
* Some statements have not been evaluated by national authorities. * Some products are not intended to diagnose, treat, cure, or prevent any disease. * For literature supporting, please contact us directly.
